UNEQUAL TREATMENT: ADDRESSING THE DRIVERS OF UNAFFORDABILITY FOR ORAL CHEMOTHERAPY

House Government Reform Committee House September 15, 2026

Official record ↗ · Linked to the scheduled hearing

Full text of the official published hearing record. Extracted from the source document — verify against the official record for citation.

[House Hearing, 119 Congress]
[From the U.S. Government Publishing Office]

 UNEQUAL TREATMENT: ADDRESSING
 THE DRIVERS OF UNAFFORDABILITY
 FOR ORAL CHEMOTHERAPY
=======================================================================

 HEARING

 BEFORE THE

 SUBCOMMITTEE ON HEALTH CARE AND 
 FINANCIAL SERVICES

 OF THE

 COMMITTEE ON OVERSIGHT AND GOVERNMENT REFORM

 U.S. HOUSE OF REPRESENTATIVES

 ONE HUNDRED NINETEENTH CONGRESS

 SECOND SESSION

 __________

 SEPTEMBER 15, 2026

 __________

 Serial No. 119-75

 __________

Printed for the use of the Committee on Oversight and Government Reform

[GRAPHIC NOT AVAILABLE IN TIFF FORMAT]

 Available on: govinfo.gov, oversight.house.gov or docs.house.gov
 
 __________
 
 U.S. GOVERNMENT PUBLISHING OFFICE
64-573 PDF WASHINGTON: 2026
======================================================================= 
 
 COMMITTEE ON OVERSIGHT AND GOVERNMENT REFORM

 JAMES COMER, Kentucky, Chairman

Jim Jordan, Ohio Robert Garcia, California, Ranking 
Mike Turner, Ohio Minority Member
Paul Gosar, Arizona Eleanor Holmes Norton, District of 
Virginia Foxx, North Carolina Columbia
Glenn Grothman, Wisconsin Stephen F. Lynch, Massachusetts
Michael Cloud, Texas Raja Krishnamoorthi, Illinois
Gary Palmer, Alabama Ro Khanna, California
Clay Higgins, Louisiana Kweisi Mfume, Maryland
Pete Sessions, Texas Shontel Brown, Ohio
Andy Biggs, Arizona Melanie Stansbury, New Mexico
Nancy Mace, South Carolina Maxwell Frost, Florida
Pat Fallon, Texas Greg Casar, Texas
Byron Donalds, Florida Jasmine Crockett, Texas
Scott Perry, Pennsylvania Emily Randall, Washington
William Timmons, South Carolina Suhas Subramanyam, Virginia
Tim Burchett, Tennessee Yassamin Ansari, Arizona
Lauren Boebert, Colorado Wesley Bell, Missouri
Anna Paulina Luna, Florida Lateefah Simon, California
Nick Langworthy, New York Dave Min, California
Eric Burlison, Missouri James Walkinshaw, Virginia
Elijah Crane, Arizona Christian Menefee, Texas
Brian Jack, Georgia Ayanna Pressley, Massachusetts
John McGuire, Virginia Rashida Tlaib, Michigan
Brandon Gill, Texas
Richard McCormick, Georgia

 ------ 

 Mark Marin, Staff Director
 James Rust, Deputy Staff Director
 Ryan Giachetti, Chief Counsel
 Andrew Goren, Legal Fellow
 Brittany Brignac, Senior Counsel
 Alex Rankin, Deputy Chief Counsel for Oversight
 Mallory Cogar, Director of Operations and Chief Clerk

 Contact Number: 202-225-5074

 Robert Edmonson, Minority Staff Director
 Contact Number: 202-225-5051
 ------ 

 Subcommittee on Health Care and Financial Services

 Glenn Grothman, Wisconsin, Chairman

Paul Gosar, Arizona Raja Krishnamoorthi, Illinois, 
Pete Sessions, Texas Ranking Member
Anna Paulina Luna, Florida Emily Randall, Washington
John McGuire, Virginia Wesley Bell, Missouri
Brandon Gill, Texas Lateefah Simon, California
 
 C O N T E N T S

 ---------- 

 OPENING STATEMENTS

 Page

Hon. Glenn Grothman, U.S. Representative, Chairman............... 1

Hon. Emily Randall, U.S. Representative.......................... 3

 WITNESSES

Mr. Ted Okon, Executive Director, Community Oncology Alliance
Oral Statement................................................... 5

Dr. Sheetal M. Kircher, MD, Associate Professor of Medicine & 
 Hematology Oncology Medical, Director of the Survivorship 
 Institute of Northwestern, Clinical Practice Director, 
 Northwestern University
Oral Statement................................................... 7

Mr. Anthony Wright (Minority Witness), Executive Director, 
 Families USA
Oral Statement................................................... 9

Written opening statements and bios are available on the U.S. 
 House of Representatives Document Repository at: 
 docs.house.gov.

 INDEX OF DOCUMENTS

 * Statement from OCRA; submitted by Rep. Grothman.

 * Statement from Cancer Support Community; submitted by Rep. 
 Grothman.

 * Statement from International Myeloma Foundation; submitted by 
 Rep. Grothman.

 * Statement from Susan G. Komen; submitted by Rep. Grothman.

 * Article, Protect Our Care, ``It is Only Getting Worse, Trump 
 Admin Cuts Medicaid''; submitted by Rep. Randall.

 * Article, The Guardian, ``TrumpRx Not A Solution For Many 
 Patients''; submitted by Rep. Randall.

 * Statement from Families USA, Trump Admin Gives Increase to 
 Insurers; submitted by Rep. Randall.

The documents listed above are available at: docs.house.gov.

 ADDITIONAL DOCUMENTS

 * Questions for the Record: Mr. Ted Okon; submitted by Rep. 
 Grothman.

These documents were submitted after the hearing, and may be 
 available upon request.

 
 UNEQUAL TREATMENT: ADDRESSING
 THE DRIVERS OF UNAFFORDABILITY
 FOR ORAL CHEMOTHERAPY

 ---------- 

 TUESDAY, SEPTEMBER 15, 2026

 U.S. House of Representatives

 Committee on Oversight and Government Reform

 Subcommittee on Health Care and Financial Services

 Washington, D.C.

 The Subcommittee met, pursuant to notice, at 10:21 a.m., in 
room 2154, Rayburn House Office Building, Hon. Glenn Grothman 
[Chairman of the Subcommittee] presiding.
 Present: Representatives Grothman, Gosar, and Randall.
 Mr. Grothman. The Subcommittee on Health Care and Financial 
Services will come to order. Without objection, the Chair may 
declare a recess at any time. I recognize myself for the 
purpose of making an opening statement.
 And first of all, like I said, I apologize for being a 
little late here. I appreciate how some of you had to come 
quite a distance to be here, so.

 OPENING STATEMENT OF CHAIRMAN GLENN GROTHMAN

 REPRESENTATIVE FROM WISCONSIN

 Welcome to today's hearing of the Subcommittee on Health 
Care and Financial Services. Today, we are examining why cancer 
patients in this country are forced to pay far more for 
chemotherapy in a pill form than the very same class of 
treatment delivered through an intravenous (IV).
 Chemotherapy is one of the oldest tools we have to fight 
cancer for decades. It was delivered almost entirely through an 
IV in a hospital or a clinic.
 Medicine, however, has changed. The Food and Drug 
Administration has now approved more than 50 oral anticancer 
medication, and it is estimated that between one quarter and 
one third of the cancer drugs in development today will be 
available only as a pill.
 For many patients, that is a breakthrough. An oral drug can 
be taken at home. It is less invasive, less disruptive, and 
just as effective as an IV infusion. For other cancers, it is 
the treatment the doctor prefers. In other words, it is better 
than an IV with an infusion. For others, it is the only option 
a patient has.
 You would think that a less invasive, at-home treatment 
would also be easier on the patient's wallet, right? You do not 
have to go to the hospital, da, da, da. Unfortunately, the 
opposite is true, and the reason has nothing to do with 
medicine. It has everything to do with how the drug is billed.
 When chemotherapy is delivered through an IV, it is covered 
under a health plan's medical benefit. The patient usually pays 
a modest co-pay, and their out-of-pocket costs are capped for 
the year. When the exact same chemotherapy comes through as a 
pill, it gets thrown onto the pharmacy benefit specialty tier.
 In other words, a flat co-pay--instead of a flat co-pay, 
the patient pays coinsurance, a percentage of the drug's price, 
and in the commercial market, that bill often has no cap at 
all.
 One in ten patients prescribed an oral cancer drug face a 
co-pay of $2,000 or more just to fill their very first 
prescription. Unsurprisingly, about one in ten patients never 
pick up their medication at all. Think about that. They got 
cancer and one in ten said I am not even going to pick it up.
 A cancer patient walks into the pharmacy holding a 
prescription that could save their life only to leave empty 
handed because they cannot afford it.
 So, who profits from, in essence, letting these people die? 
The answer far too often is the middlemen, the pharmacy benefit 
managers, or PBMs. The three largest of these companies are 
also owned by the Nation's largest health insurers. Okay. They 
decide which drugs a plan will cover, which the patient pays, 
and they collect rebates calculated as a percentage of the drug 
list prices.
 The Federal Trade Commission has found that the largest 
PBMs marked up specialty drugs, including oral cancer drugs, by 
hundreds and even thousands of percent when they were dispensed 
through the pharmacies these same companies own, pocketing 
billions of dollars in the process. In other words, a way to 
make more money, not to do its best in the patient's own 
interest.
 And I think the system, as a whole, does not save any 
money, and when they are not marking up the price, they are 
delaying the care through prior authorization, through failed 
first-step therapy, and forcing patients to fill their 
prescriptions through these same company-owned pharmacies, 
right?
 If you just give them the drug in the first place, save a 
little money, but even more, save lives. And when they are not 
marking up the price, they are delaying the care.
 Forty-three states have passed laws to fix this, including 
my own State of Wisconsin, requiring that oral and IV 
chemotherapy need to be treated the same. But those state laws 
cannot reach employer plans that cover most working Americans 
because Federal law preempts what the state legislatures are 
doing. Only Congress can close that gap.
 That is why I personally have introduced the Cancer Drug 
Parity Act, which is bipartisan with a straightforward premise. 
A healthcare plan cannot charge a patient more for oral cancer 
than for IV treatment it is already covering.
 This hearing will highlight how the problem took root, how 
middlemen are harming patients, and what Congress has to do to 
improve the lives of cancer patients across the Nation, and 
increase the chance that you will live through cancer.
 We are honored to have expert witnesses here with us today 
to help us examine this crucial issue.
 With that, I yield to--you do not look like Member 
Krishnamoorthi. With that, I yield to Congresswoman Randall for 
your opening remarks.

 OPENING STATEMENT OF EMILY RANDALL

 REPRESENTATIVE FROM WASHINGTON

 Ms. Randall. Thank you, Chair Grothman.
 I appreciate finally having a hearing again in this 
Subcommittee. It has been nine months since we have gotten 
together, nine months since the Majority has chosen across many 
committees to hold bipartisan--or to hold partisan roundtables 
instead of hearings. So, it is great to be back in this room 
for a hearing.
 I am pleased to be filling in for--as the Ranking Member 
today, and to discuss the ways that healthcare has become 
unaffordable and inaccessible. Rising healthcare costs are a 
constant concern for me, as they are for so many millions of 
Americans.
 Daily life is increasingly unaffordable, and the cost of 
healthcare is a huge driver. Choosing between healthcare and 
other essentials like food, rent, childcare, is keeping 
Americans up at night.
 And I know that government can help. My younger sister, 
Olivia, was born with complex disabilities, and because of 
Medicaid expansion, my family was able to keep our home and 
afford her care, and she was able to live a thriving life for 
19 years.
 Every family should have the ability to care for their 
loved ones. No one should have to worry about how or even if 
they can afford healthcare. We should be working to bring down 
the costs and bring down healthcare prices and improve access 
to care so that quality care is available to all, including 
those in rural communities like mine.
 The cost of healthcare can haunt families for years, and 
many Americans struggle to survive the crushing weight of 
medical debt. Because of soaring healthcare costs, medical debt 
is an issue that disproportionately impacts people of color, 
women, families, and those without insurance. Addressing these 
disparities is absolutely vital, if we are to have a healthcare 
system that is affordable, accessible, and improves outcomes 
for Americans regardless of where they live or how much money 
they have.
 And the high cost of medication is a big part of the 
problem, including oral chemotherapy. In one recent survey, 
almost half of the respondents reported being underinsured for 
prescription medications. Even with insurance coverage, they 
could not afford all of the medications they need. This should 
concern all of us, and I am so grateful to hear the Chairman 
lay out some of the problem with oral chemo, especially.
 The Trump Administration and my Republican colleagues, 
however, have only made the problem worse over these last two 
years. Policies that are making healthcare coverage more 
expensive have been passed by this Majority, and they have 
significantly cut funding to vital medical resources and 
programs across the country.
 The Republicans' so-called Big Beautiful Bill Act cut 
Medicaid, stripping millions of their healthcare coverage. Then 
Congressional Republicans refused to extend the Affordable Care 
Act (ACA) tax credits that helped people afford their insurance 
premiums. These unconscionable actions only led to skyrocketing 
healthcare premiums and out-of-pocket costs for families across 
the country.
 In effect, Republicans in Washington have traded your 
healthcare for tax breaks for billionaires. Under Republican 
leadership, up to ten million people are estimated to have 
already lost their healthcare coverage. This means an 
additional ten million people struggling to see a doctor or pay 
for a prescription. They have created an environment where yet 
another person and another family are forced to choose between 
their health or rent.
 And that is not all. The Trump Administration also canceled 
$160 million in funding for Washington State that was meant to 
support disease monitoring and vaccine programs, and these cuts 
also make Americans less safe and risk their health.
 At the same time the Congressional Republicans are making 
healthcare more expensive and harder to access, the Trump 
Administration is also destroying the research and innovation 
we rely on to cure diseases like oral cancer, improve 
treatments and advanced healthcare.
 The Administration has terminated, suspended, or otherwise 
disrupted thousands of grants resulting in a loss or disruption 
of over $16 billion in scientific research. These cuts have 
caused a major disruption in our Nation's scientific research 
engines and are costing lives.
 This hits particularly close to home. Cancer patients from 
across the Olympic Peninsula and across the country travel to 
receive treatment from the Fred Hutchinson Cancer Research 
Center in Seattle, a world-class research institution that has 
been affected by Federal funding cuts and staff reductions.
 Cutting cancer research is evil, full stop. This 
Administration has robbed our society of new treatments and 
cures, and cancer patients and their loved ones will suffer.
 Early career researchers are now choosing different 
research paths because of the instability that President Trump 
has created. Cancer patients and others are facing terrible and 
deadly diseases and are suffering more after promising clinical 
trials have been canceled.
 Costs are rising every day, and the Trump Administration is 
only making things harder and more expensive for our American 
families. The Republican Majority in Congress could have done 
more to stop it, but has enabled President Trump in ripping off 
the American people.
 I am glad that we are holding a hearing today. The high 
cost of oral chemotherapy needs fixing, and it sounds like we 
are aligned on some of those issues, but that is just one piece 
of our healthcare challenges. Countless medications are out of 
reach for far too many families.
 This is the very first hearing on high drug costs in this 
Subcommittee, and it is the last hearing this Committee will 
hold before Americans go to the polls to elect a new Congress. 
We should remember that this is far too little and far too 
late.
 Thank you. I yield back.
 Mr. Grothman. Okay. I do not exactly want to respond to 
that, but I will say this. This hearing is focused on oral 
chemo. We know there are people who feel it would be better if 
the government took over the entire healthcare system.
 That does not work anywhere else that I am aware of. There 
has been tons of fraud, and more fraud will be soon shown in 
the current Medicaid system, saving billions of dollars. And I 
am going to, from here on out, just say that, you know, having 
the government run anything does not seem to work very well. 
That is why our country is so much wealthier than other 
countries, and we will continue to try to work to improve the 
current system.
 But right now, we are going to focus on community oncology. 
I would like to welcome today's witnesses. Mr. Ted Okon serves 
as Executive Director for the Community Oncology Alliance. Mr. 
Okon is a nationally recognized expert on the policy and 
politics of cancer care with an expertise in cost of cancer 
treatments; healthcare reforms; pharmacy benefit managers, or 
PBMs; and the changing landscape of cancer care delivery in the 
United States.
 Then we have Dr. Sheetal Kircher, a practicing oncologist 
and associate professor of medicine at Northwestern Medicine. 
Dr. Kircher also serves as the Clinical Practice Director and 
Medical Director of the Cancer Survivorship Institute of 
Northwestern's Robert H. Lori Comprehensive Cancer Center. In 
this role, Dr. Kircher oversees the program's expanding 
clinical survivorship care and research and long-term effects 
of cancer treatment.
 And finally, Dr. Anthony Wright, Executive Director of 
Families USA, a national healthcare consumer advocacy 
organization. Before joining Families USA, he spent 22 years as 
Executive Director of Health Access America.
 Thank you all for joining us, and I am going to look 
forward to your testimony.
 Now, pursuant to--oh, by the way, I also want to submit for 
the record a statement from the International Myeloma 
Foundation. I have currently a very loved family member with 
myeloma.
 We have a statement from the Cancer Support Community that 
I want to submit for the record and a statement for the record 
from Susan G. Komen on ``Unequal Treatment: Addressing the 
Drivers of Unaffordability of Oral Chemotherapy.''
 Now, pursuant to Committee Rule 9(g), the witnesses will 
please stand and raise your right hand.
 Do you solemnly swear to affirm that the testimony that you 
are about to give us is the truth, the whole truth, and nothing 
but the truth, so help you God?
 [Chorus of ayes.]
 Mr. Grothman. Let the record show that all the witnesses 
answered in the affirmative. Thank you.
 You may now take a seat, and we will first call on Mr. 
Okon.

 STATEMENT OF MR. TED OKON

 EXECUTIVE DIRECTOR, COMMUNITY ONCOLOGY ALLIANCE

 Mr. Okon. Thank you, Chairman Grothman, acting Ranking 
Member Randall, and Members of the Committee. Thank you for the 
opportunity to testify today.
 I am the Executive Director of the Community Oncology 
Alliance (COA), a nonprofit organization advocating for cancer 
patients and the independent practices providing the highest 
quality and most affordable cancer care close to home.
 I want to begin with a core principle. A cancer patient 
should not pay more for their cancer drugs simply because the 
medicine that may save or extend their life comes in a pill 
rather than an IV bag. Yet, that happens today.
 Cancer treatment has changed dramatically. Roughly, one-
third of cancer therapies today are oral, and that share 
continues to grow. But because oral cancer drugs are generally 
covered under the pharmacy benefit, while infused or injectable 
drugs are covered under the medical benefit, patients can face 
very different and sometimes higher out-of-pocket costs simply 
because of how their cancer medicine is administered. That 
makes absolutely no sense.
 COA supports the goal of Cancer Drug Parity Act, H.R. 4101, 
which requires employer-sponsored health plans to provide cost-
sharing for oral cancer drugs that is no less favorable than 
cost-sharing for cancer drugs administered by a healthcare 
provider.
 Importantly, the legislation also prevents plans from 
achieving so-called parity by simply increasing what patients 
pay for infused cancer drugs.
 Congress must pass that protection, but I strongly urge 
Congress to view parity as only the beginning of the 
discussion, not the end. Parity is just the floor. Access and 
affordability are the goal.
 If a patient pays thousands of dollars for a medically 
necessary cancer drug, it offers little comfort that the 
coinsurance is technically equal to another benefit. Our 
collective goal should be to minimize the financial burden on 
patients receiving potentially lifesaving cancer treatment.
 And there is another equally important problem with 
potentially lifesaving cancer drugs. A cancer drug that a 
patient cannot actually obtain is no more accessible than a 
cancer drug that the patient cannot afford.
 Today, insurers and their pharmacy benefit managers place 
obstacle after obstacle between patients with cancer and the 
medications prescribed by their oncologists. Prior 
authorization all too often delays treatment. Fail first step 
therapy can require a patient to try and fail a plan preferred 
drug before receiving the therapy the treating oncologist 
believes is optimal.
 Restrictive formularies often exclude drugs or place them 
on unfavorable tiers. Patients can be forced into insurer PBM 
specialty and mail order pharmacies, rather than receiving 
their medications directly from the oncology practice 
coordinating their care, and patients successfully receiving a 
treatment can face nonmedical switching simply because the 
insurer or the PBM changes its formulary.
 COA's 2026 survey of community oncology practices found 
that more than 96 percent of respondents had observed patients 
with cancer struggling as a direct result of insurer-imposed 
step therapy. The same percentage was reported that insurance 
policies interfere with patients receiving the treatment their 
physician recommends first.
 For patients with cancer, the concept of fail first is not 
only disturbing, but it is scary and devastating.
 Cancer is a disease where you effectively lose control of 
your body. You should not lose control of the medication to 
save your life. A drug preferred on an insurer PBM formulary is 
not necessarily the least expensive drug for the patient, or 
the drug the oncologist believes is best; it is often a drug 
that generates the greatest rebate or financial return for the 
middleman.
 Cancer treatment decisions should be made based on the 
patient's diagnosis, biomarkers, prior therapy, comorbidities, 
expected toxicity, and the best clinical evidence. They should 
not be driven by what drug generates the greatest financial 
return for the PBM or the insurer.
 Congress should build on H.R. 4101 and other legislation 
intended to remove the cost, delays, and denials that prevent 
cancer patients from receiving their optimal cancer treatment. 
Congress should minimize percentage-based coinsurance for 
medically necessary cancer drugs. Inappropriate fail first step 
therapy and nonmedical switching should be prohibited.
 Prior authorization should be dramatically streamlined with 
enforceable deadlines, meaningful exceptions, and reviewed by 
physicians with real oncology expertise. And insurers and PBMs 
must be stopped from steering cancer patients to affiliated 
mail order and specialty pharmacy simply because it is the most 
profitable to the middleman, the corporate middleman.
 Let me close with this: Cost parity is the floor. Access 
and affordability are the goal because parity without access 
and affordability is not really parity.
 Cancer patients should not have to fight their cancer, 
fight unaffordable cost-sharing, and then fight an insurance 
company or PBM simply to receive the medicine their doctor 
prescribed. Congress can and must change that.
 Thank you, and I look forward to your questions.
 Mr. Grothman. Thank you.
 Now we will call on Dr. Kircher for your statement.

 STATEMENT OF DR. SHEETAL M. KIRCHER, MD

 ASSOCIATE PROFESSOR OF MEDICINE &

 HEMATOLOGY ONCOLOGY MEDICAL DIRECTOR OF THE

 SURVIVORSHIP INSTITUTE OF NORTHWESTERN

 CLINICAL PRACTICE DIRECTOR

 NORTHWESTERN UNIVERSITY

 Dr. Kircher. Chairman Grothman, Ranking Member Randall, and 
Members of the Subcommittee, thank you for the opportunity to 
testify.
 My name is Dr. Sheetal Kircher. I am a medical oncologist 
at Northwestern in Chicago where I treat patients with 
gastrointestinal cancers. I am here today because my patients 
are not only dealing with their cancer diagnosis, but they are 
trying to figure out how they are going to afford the drugs 
that I am prescribing them.
 Cancer treatment has changed dramatically. When people 
think about those receiving chemotherapy, they often imagine a 
person in an infusion center receiving an IV. But increasingly, 
some of our most effective drugs are pills taken at home, and 
sometimes this pill is not just an alternative convenient 
switch. It is sometimes the best treatment or the only 
treatment that is appropriate for that patient, and our 
insurance system has just not kept up pace with that science.
 An IV drug, like we have all mentioned, covered under our 
medical benefits, and oral drugs covered under the pharmacy 
benefits, this is not just a technicality of insurance design. 
To a patient with cancer, it determines whether they actually 
get their treatment.
 And so, this is what it looks like in my clinic: On 
Wednesday, August 26, I was walking down the hall of my clinic 
to see Susan, a 62-year-old schoolteacher. She is a wife, 
grandmother, had about eight grandkids, and also has metastatic 
pancreatic cancer.
 I was holding the printout of her scans walking into that 
room, and the scans, they showed that her cancer was growing 
despite the IV chemotherapy I was giving.
 After 17 years of doing this work, I still have to pause 
when I walk into those rooms. I take a deep breath knowing that 
the words are going to take away some of her hope and force 
them to, once again, confront her mortality.
 And literally, as I am walking into that room, I step in, I 
receive a notification on my phone, and it is an FDA has just 
approved daraxonrasib, a new treatment for metastatic 
pancreatic cancer. And for a few minutes, that room was purely 
filled with hope that there was something that was going to 
give Susan just a little bit more time.
 That hope is quickly followed by a reality I knew was 
coming, that prescribing the drug and getting the drug are two 
different things.
 With her IV chemo, my infusion center obtained 
authorization. Patient shows up for chemotherapy. We administer 
the treatment, and it goes through her medical benefits. The 
experience is completely different for a patient receiving oral 
drugs.
 With IV, the patient may absolutely have co-pays and 
coinsurances, and those costs can be significant, but most have 
a supplement coverage, or an employer-based plan design that 
limits the amount they pay at the point of treatment. The 
patient is not standing at our infusion center door being told, 
before we hang your bag of chemotherapy, you need to pay 
$1,000.
 And for oral drugs, that experience is really quite 
different. The specialty pharmacy processes a prescription, 
determines the out-of-pocket responsibility, which can be 
substantially higher than the medical benefit. That cost 
becomes apparent before the drug is dispensed.
 Too often, our health system specialty pharmacy is out of 
network, even at a large institution, forcing a prescription to 
a PBM-owned pharmacy, separating the dispensing of these 
expensive, toxic drugs, and really divorcing them from the 
oncology team which is providing the education and the care to 
the patient.
 And the patient can essentially receive a phone call saying 
we have your cancer medication. Your responsibility is $1,000. 
How would you like to pay for that before we ship it? If they 
cannot afford that amount, the drug is not dispensed, and we 
are left trying to find another way to pay for it.
 And we know this cost matters. In a study of over 10,000 
patients prescribed these drugs, if the out-of-pocket cost was 
over $500, they were four times more likely to abandon the drug 
than if it was $100 or less. And in oncology, a prescription 
that a patient cannot afford is not a treatment.
 IVs also mean transportation, parking, waiting rooms, hours 
at infusion centers, not for the patient alone, but also for 
their loved ones. And oral drugs face additional obstacles, 
they require prior authorizations, formularies, step therapy 
changes, and really required to go through other particular 
PBM--often owned specialty pharmacies.
 The amount of time my nurses and advanced practice 
providers spend doing this, in addition to myself, is 
extraordinary when this is time we should be spending with our 
patients.
 And I understand that the Cancer Drug Parity Act does not 
solve all of these problems. It does not eliminate prior 
authorizations, and it does not solve our PBM issues, but it 
does fix something very specific that has never made sense to 
me clinically.
 As an oncologist, I choose treatment based on biology, 
science, expected benefits, toxicities, and what matters to 
that person sitting right in front of me. Sometimes it comes 
through an IV and sometimes it is oral.
 On August 26, Susan did not choose whether her breakthrough 
was going to be developed as an infusion or a pill. She should 
not experience a completely different financial reality because 
her next treatment is swallowed instead of infused.
 That is why the Cancer Drug Parity Act matters to me. The 
science should determine the treatment.
 Thank you.
 Mr. Grothman. Okay. Thank you.
 Mr. Wright, I guess like the others, we will give you 5-1/2 
minutes.

 STATEMENT OF MR. ANTHONY WRIGHT (MINORITY WITNESS)

 EXECUTIVE DIRECTOR, FAMILIES USA

 Mr. Wright. Thank you, Chairman Grothman, Representative 
Randall, and Members of this Subcommittee. Thank you for having 
me here on behalf of Families USA, the national, nonpartisan 
healthcare consumer advocacy organization.
 We appreciate the Committee's interest in addressing the 
drivers of the unaffordability of cancer treatments and 
ensuring that oral chemotherapy is appropriately covered.
 Cancer impacts millions of American families. More than two 
million cancer cases will be diagnosed this year alone, 
including my wife, just a few weeks ago.
 As I and millions more know personally, a cancer diagnosis 
is frightening enough on its own. No family should have to 
fight a second battle over how to afford the treatment.
 Even for people with private coverage, the cost of 
anticancer drugs can be staggering. Take Keaton Herzer, a 34-
year-old from Colorado who was diagnosed with rare bile duct 
cancer. The day before his infusion of a targeted therapy, his 
health plan denied coverage despite his oncologist's 
recommendation and advocacy.
 Rather than delay what could jeopardize a shot at a much-
needed liver transplant, Keaton and his wife emptied their 
savings account and paid for it out of pocket. $77,000 for a 
single treatment.
 Take Jen Jobe, a Texas teacher who beat stage four colon 
cancer and is now saddled with major medical debt. The cost of 
a single chemotherapy treatment was enough to reach her $8,500 
annual out-of-pocket maximum. Over the course of treatment, she 
racked up $40,000 in out-of-pocket costs despite her employer 
on-the-job benefit.
 These stories illustrate the big cost of cancer care, the 
need to be covered, and for that coverage to be comprehensive 
without delays, denials, sky-high deductibles, or other cost 
barriers.
 Health plans certainly need more oversight, especially if 
benefit designs develop in corporate boardrooms without public 
input as they seek to minimize their risk and shift the cost 
onto the consumer.
 Congress should follow the lead of state marketplaces that 
standardize plans to ensure essential benefits and fair and 
valued-based cost-sharing. More than half the states have also 
passed co-pay caps for prescription drugs with eight that have 
specific caps for specialty drugs, like oral chemotherapy.
 Similarly, 43 states have passed parity laws so cancer 
patients do not face different financial barriers for IV 
administered treatments versus oral chemotherapy often covered 
in a separate drug benefit with its own deductibles, specialty 
tiers, coinsurance, and other cost-sharing.
 We support the Chairman's bipartisan Cancer Drug Parity 
Act, which covers Federally regulated employer plans that 
states cannot touch and other efforts to ensure that all 
coverage is comprehensive and cost-sharing is limited.
 Yet, cancer patients with non-employer plans also need 
comprehensive coverage. Yet, ten million Americans are 
projected to lose coverage because of Congress' cuts to 
Medicaid and the Affordable Care Act. Just this year, four 
million Americans dropped their individual coverage due to the 
doubling of premiums resulting from the deliberate decisions to 
end the enhanced tax credits. A few million more dropped down 
to bronze plans with deductibles of $7,000 or more.
 We urge this Committee to consider the millions of nearly 
uninsured and underinsured, including those who will inevitably 
become cancer patients and face the full cost of cancer care.
 For all consumers, regardless of how or whether they are 
covered, we must confront the inflated and irrational prices of 
prescription drugs. Nearly one in three adults reported not 
taking their medications prescribed, rationing, skipping doses, 
not filling their prescriptions at all. An estimated 125,000 
people die each year as a result.
 Drug companies have long exploited a system that lets them 
set a high launch price with no accountability and then raise 
prices faster than inflation.
 Thankfully, Medicare drug price negotiation and a new 
$2,000 out-of-pocket cap is starting to lower drug costs for 
millions of seniors and people with disabilities, but the 
Inflation Reduction Act's negotiating power is limited to 
Medicare. We must expand negotiation to more drugs and to more 
people, including with commercial coverage.
 Congress must also shut down problematic pricing and 
practices, like patent gaming, and pay for delay tactics that 
keep cheaper generics and biosimilars out of the market.
 In closing, Americans are urging action on prescription 
drug prices and healthcare costs in general. Our Families USA 
poll last month showed that 94 percent of voters said it is 
important that Congress and the President act on healthcare 
costs. Seventy-four percent said very important.
 They want Congress to address affordability and hold the 
health industry accountable, from the drug companies to the 
health plans, to the providers, to the PBMs.
 Cancer patients like Keaton and Jen deserve more than 
parity between two unaffordable treatment options. They deserve 
a system where the cost of staying alive also does not threaten 
their families' financial future.
 Thank you, and I look forward to your questions.
 Mr. Grothman. Okay. I would like to thank you all very 
much. Now we are going to the question and answer.
 I also want to give a little shout out before we start. As 
far as the overall cost of drugs, I know it is, you know, drug 
by drug, but TrumpRx is the first time in the 12 years that I 
have been here that we have really had somebody willing to 
stand up to the pharmaceutical industry and drop the price of 
drugs. And while that is not going to be as comprehensive as 
what we are going to talk about today, it was a great step, and 
I would like to thank the President for that.
 Okay. Now we will start the questions. I recognize myself 
for 5 minutes.
 Medicine has changed, more and more cancer is being treated 
with oral medication. The patients take it at home rather than 
through IV infusions. For many patients, oral chemo is the 
safer, easier, and more effective option, but the way these 
drugs are paid for has not kept pace with the change.
 I would like to ask both Mr. Okon and Dr. Kircher, can you 
explain in plain terms how our insurance rules have failed to 
keep up with the science and who ends up paying the price for 
this failure?
 Mr. Okon. So, I think, Mr. Chairman, part of the problem is 
you identified in your remarks that the PBMs, basically three 
PBMs, control 80 percent of the prescription drug market. You 
have to realize, each one of those PBMs is owned by an 
insurance company. In fact, in some cases, the insurance 
company owns the physicians as well, too, with United 
Healthcare.
 So, the problem is that as these companies have seen these 
oral cancer drugs and upwards of 30 percent, we are going on 40 
percent of cancers are treated with oral cancer drugs, you have 
to realize that they are gold to these PBMs. They are gold, 
especially when they can extract rebates and do other 
mechanisms to make off of these drugs, and they always push the 
highest-priced drugs.
 So, the fact of the matter is that this has attracted them 
to a market that is just going to increase, and it is just 
going to get worse.
 Dr. Kircher. Yes, I agree. And, you know, I think in cancer 
specifically, the drugs have changed so much over the last 20, 
30 years where we did use to only have IV chemotherapy. And 
even in the 15 years that I have been practicing, the science 
has evolved in a space where--not only orals. We are talking 
about the next level of now we are going to have, you know, a 
lot more immunotherapy, CAR-T therapy, different type of 
infusions that will need to keep up with this antiquated way 
that we really finance the chemotherapy, locking us into a 
bucket that really does not make sense for oncology anymore.
 Mr. Grothman. Okay.
 The medical providers that are members of the Community 
Oncology Alliance, or COA, treat most of the cancer patients in 
our country. As COA's Executive Director, you have spent years 
fighting the industry practices, again, between patients and 
their prescribers.
 Could you explain to us how PBMs and insurers often 
interfere with a patient's prescribed oral chemo treatment?
 Mr. Okon. It is terrible. First of all, when the drug is 
prescribed, if the insurer or the PBM, with prior 
authorization, does not agree with that, then the oncologist 
basically has to make a switch, or, in some cases, the insurer 
will basically say, you have to fail first on this drug, and in 
some cases a couple of times you have to fail.
 Think about that cancer patient when someone says you have 
to fail on that drug, meaning your cancer is growing before you 
basically get the drug that they want.
 And, again, I go back to the issue here. When you have 
three entities that control 80 percent of the prescription drug 
market, they are in a leveraged position to extract rebates, 
and, therefore, they look for the most expensive drugs, the 
drugs that they can profit the most from as the drugs that they 
want the patient to get, not what the oncologist wants.
 So, it is a growing problem, especially as we have more 
oral drugs. Why didn't we see this ten years ago? Because we 
did not have the oral drugs that we have now. It is just going 
to get worse, and it is going to get worse until we do 
something about these PBMs and insurers.
 Mr. Grothman. Thank you. We have dealt with the PBMs in 
other hearings.
 Dr. Kircher, for some cancers, an oral drug is not just 
more convenient, it is the treatment that works best, and it is 
the only option a patient has. When a plan makes this option 
unaffordable but covers the IV drug cheaply, are we forcing 
patients toward a more dangerous alternative?
 And does the doctor, who ultimately, you know, as you are 
relying on, do they know what is going on?
 Dr. Kircher. Thank you for that question. And I think that 
is a misconception that these drugs are alternatives. They are 
actually completely unique identity, you know, identifiable 
drugs where I, as a physician, am not making a choice. I do not 
have a choice oftentimes for an IV alternative.
 So, there are times, absolutely, where I cannot get my oral 
drug quick enough, fast enough, and I will need to start 
patients on IV therapy because I can get it approved quicker.
 I absolutely agree with your question that, yes, that 
oftentimes does put patients in a toxicity space that I would 
rather not them be in, and I am doing it mainly based on the 
fact that I need to treat their cancer quickly.
 Mr. Grothman. Thank you.
 Okay. We have taken that time.
 Ms. Randall.
 Ms. Randall. Thank you, Mr. Chair, and thank you, again, to 
our witnesses for being here today.
 As I mentioned at the start, last year, H.R. 1 was the 
beginning of stripping health coverage away from 15 million 
Americans. Rural hospitals, nursing homes, and community health 
centers who often are providing important, lifesaving 
healthcare to cancer patients, are under severe strain, forcing 
many to reduce services or close them altogether.
 Many rural hospitals are choosing whether or not they can 
continue offering oncology and cancer services, or if their 
patients are going to travel hours farther to go to another 
treatment center that still provides that care, pregnant women 
are being forced to travel greater distances to access 
maternity care, seniors struggling to find long-term care, 
people with disabilities experiencing serious disruption to 
essential services.
 Sarah in Takoma, Washington, wrote to me that she is a 
breast cancer survivor who was diagnosed with an aggressive 
form of a disease just before her 41st birthday. She credits 
decades of federally supported research with helping make her 
survival possible.
 And now, at 44, and two years past active treatment, she 
continues to live with the fear of recurrence while watching 
for the next breakthrough. Her story is a reminder that 
research breakthroughs become lifesaving treatment, and 
Congress must protect Federal investments and cancer research 
and ensure that these treatments are affordable and accessible.
 In the richest country in the world, as the Chair pointed 
out earlier, that we are, it is unacceptable that we allow 
high, out-of-pocket costs to stand between patients and the 
advances that research makes possible.
 Mr. Wright, my question is for you. Oral chemotherapy can 
be particularly difficult to access for patients in underserved 
communities where lower incomes, gaps in insurance coverage, 
limited access to oncology care, other barriers, can compound 
and burden the high out-of-pocket costs.
 What do you see affecting most patients in rural, low-
income, and other underserved communities in preventing them 
from getting access to care?
 Mr. Wright. Obviously, the issues of access in rural 
healthcare is significant already. We used to say, as you 
mentioned, that the cuts that were made last year, the biggest 
cuts in the history of the Medicaid program, will make that 
issue worse, especially for providers where Medicaid is the 
primary payer, and that includes rural hospitals; that includes 
maternity wards; that includes community clinics and a range of 
other providers that will have to either scale back services or 
maybe even close as a result.
 I also think that these cuts have an impact both on moving 
people off of coverage, again, estimated millions of people who 
will face the full force of cancer costs if they do get cancer 
while uninsured or underinsured. And even if they are insured, 
they will have a harder time getting access to the care that 
they need.
 And even trying to get through some of the bureaucratic 
burdens, you have a situation where the Trump Administration 
has gone further than the law that was passed by saying that, 
yes, we are going to exempt people who are medically frail from 
these requirements, but we are going to actually have to have 
everybody go get a doctor's note.
 We are not going to blanket, say, folks with cancer have 
this, and we are going to put additional bureaucratic burdens 
even for cancer patients to get the care that they need.
 Ms. Randall. Thank you so much for that perspective.
 As we know, the cost of healthcare can lead many to putting 
off much-needed care. And it is not a red state versus blue 
state issue, right? I represent Washington State, but these 
huge cuts affect everyone.
 Texas hospitals are facing a roughly $9.8 billion loss in 
additional Medicaid funding this fiscal year, about $27 million 
a day, funding that helps hospitals cover the gap between 
Medicaid payments and the actual cost of caring for patients 
who need, often expensive, treatment.
 Mr. Wright, you shared so much about the patient experience 
with us. For oral chemotherapy in particular, how much of the 
financial burden patients face today is driven by the 
underlying price of the drug itself versus the way insurers 
structure coverage?
 Mr. Wright. I think it is both. I think the drugs are very 
expensive. And, again, we give them a monopoly, but, in many 
cases, they abuse that monopoly, that patent, with games to try 
to extend that monopoly to have more time to charge the 
monopoly price. And then the insurers pass that cost on to 
consumers and try to limit their risk with the types of benefit 
designs.
 And that is why we need to have oversight over benefit 
designs. Cancer parity is one example, but there are other ways 
to put caps or other ways to make sure that we have 
standardized plans so people have assurance that essential 
benefits are covered, and they can do apples-to-apples 
comparison.
 Ms. Randall. Just a unanimous consent--I am done with my 
questioning. Thank you.
 I ask for unanimous consent to enter into the record an 
article from The Guardian which shows how TrumpRx is not a 
solution for the majority of patients dealing with high drug 
prices. And also, for unanimous consent, to enter into the 
record a report from Protect Our Care, which found that the 
Trump Administration's actions threaten the closure of over 
1,200 hospitals, clinics, and nursing homes, jeopardizing 
access to care.
 Mr. Grothman. Okay. Without objection.
 I will say right now, we will see how many more people show 
up for this Subcommittee, but we are going to have two rounds 
of questioning, so if you want to hang around.
 Now we will go to the great Paul Gosar.
 Mr. Gosar. Well, you both--all of you may not know I was a 
dentist for 25 years, okay. So, I was looking at marketplaces.
 So, Mr. Wright, I am going to ask you this question. How 
has the patent process really affected this? Because once upon 
a time, it used to be first to discover instead of first to 
file.
 Mr. Wright. Again, I think we have a drug development 
process where those who file the patent get the benefit of 
several years of charging monopoly price.
 I do think that the opportunity for Congress is to take a 
look at ways that that patent has been gamed, whether from 
patent gaming, trying to extend the patent, pay for delay 
settlements where they actually do settlements to the potential 
generic competitor to keep competition from the market.
 Mr. Gosar. I think as a preliminary force, and we have to 
go back and address this because there once was a law called 
McCarran-Ferguson that gave limited liability to insurers for 
that monopoly rule, but they were running a freight train 
through that thing. It was my legislation that repealed that. 
Now, I think we ought to be looking back at that one. Do you 
agree?
 Mr. Wright. I would be happy to take a look at it.
 Mr. Gosar. Great, great, great.
 So, what if I told you that part of this is the Federal 
Government's problem, Mr. Okon? So, back in 2007, we knew that 
with cancer drugs, that the IL-15 was a marker that actually 
exposed the tumor, and then you could use your own genetics in 
your immune system to kill it off. That was known in 2007.
 Why do we have this? As we see now, Keytruda is an I-2 
drug. It does not do that. And yet, Anktiva is the one that 
exposes those tumors and lets your immune system take care of 
it. This has been known since 2007 in the FDA.
 What is the problem? Why isn't this being directed, and why 
is it so expensive?
 Mr. Okon. I cannot really explain that, Congressman. I 
mean, the fact of the matter is that in the--and Dr. Kircher 
could talk about this.
 Mr. Gosar. I will come back to her.
 Mr. Okon. We have more drugs, and more novel drugs. She 
talked about CAR-T and talked about not just the immuno agents 
that we see in terms of Keytruda and Opdivo, but we are seeing 
cellular therapies come out that are using the body's own 
mechanism to heal.
 And I think that, basically, you are going to see a lot 
more of this, and they are very novel. And how we pay for those 
and the mechanism has to be looked at as well, too, because it 
is not just, as the Chairman said, going from, you know, 
injectable chemotherapy that you think of traditionally to oral 
drugs. It is now cellular therapies and different things, and 
we have a payment mechanism that is archaic and not keeping 
pace.
 Mr. Gosar. I am glad you said that, because, you know, 
bringing in the Ranking Member's comments, I agree with her. 
The lady with breast cancer, why she was not given Abraxane, I 
do not know. You know, it is criminal what is going on here, 
absolutely criminal what is going on here.
 So, you know, I think we ought to start from the very 
bottom, increasing competition so that nobody can look. Do not 
allow any limited liability for the insurance companies. Make 
them compete. Make them compete.
 And we are so far behind. There are 34 countries, 35 
countries I believe now, that give the exemption to insurers 
that they have Abraxane and then you have this Keytruda.
 Doc, what do you see in your practice?
 Dr. Kircher. I mean, really just echoing the sentiment up 
here, is that we need innovation in cancer treatment. We need 
these types of treatments to move forward, and they are 
expensive, and they take a lot of research and development. So, 
you know, comprehensive healthcare reform and price reform. 
Drug parity is just one piece of this very complicated puzzle. 
Knowing that stifling innovation is not what our cancer 
patients need, but leaving behind a legacy of financial 
devastation also cannot be, and how do we find the middle 
ground?
 Mr. Gosar. Exactly. I want to come back to that.
 I want to talk about, you know, the opportunity for the 
right to try. Why isn't it getting the vestige that it should 
be? Because I think there is a lot more to the story than meets 
the eye.
 I will yield back, and I will look forward to the second 
round.
 Mr. Grothman. I ask unanimous consent for a second round of 
questions for the Members. Without objection, so ordered. You 
are not objecting, are you?
 Ms. Randall. I am not objecting.
 Mr. Grothman. Okay. First of all, I will make a point 
outside of this. We may or may not have other people show up 
for the Subcommittee, I will make a point that we should do 
something about Subcommittee attendance later on. Okay.
 Mr. Gosar. Well, I will tell you, I enjoyed this. I get an 
unlimited number of questions today.
 Mr. Grothman. I know.
 Mr. Gosar. I will tell you that right now.
 Mr. Grothman. All the more importance for the people who do 
show up.
 Mr. Okon, this is for you, 43 states and the District of 
Columbia have already passed oral parity laws. I believe I 
voted for such a law when I was in the state legislature in 
Wisconsin. But those state laws do not reach self-funded 
employer plans, so those states do not--so those state laws do 
not reach self-funded employer plans, which cover roughly two-
thirds of Americans. So, you know, if you are sitting back home 
and you hear this, you thought, wait, I thought my state took 
care of it, not if you are part of a self-funded employer plan.
 The Cancer Drug Parity Act, which I reintroduced this 
Congress, closes the employer-plan gap by amending ERISA so a 
plan covering IV anticancer drugs must offer cost-sharing for 
medically necessary oral anticancer drugs on terms no less 
favorable that the IV alternative.
 In practical terms, what changes would a patient at the 
pharmacy counter see if this bill becomes law?
 Mr. Okon. Well, I think the beauty of it is, Mr. Chairman, 
is that now on a Federal level, you basically have parity for 
those self-funded plans. So, it fills in the gap that you have 
with those 43 states, that is just under state law.
 So, I think it is an absolute step in the right direction. 
I think what we need to build on it, as I said, and Dr. Kircher 
said as well, too, is we need to build on it in terms of having 
no prior authorization, and no fail-first step therapy as well, 
too.
 But everything we do, we have to understand, everything 
that Congress does here is a step in the right direction in 
terms of PBMs and insurers, and certainly oral cancer parity.
 Mr. Grothman. Dr. Kircher, I am going to ask you this: 
obviously the current system is broken. We have people dying 
unnecessarily because they cannot get the drugs they have. The 
question is, who exactly, because overall this should be, I 
would think, cheaper overall, right, because you are not going 
through this first step, sort of, nonsense in which somebody is 
paying the cost there, who is making the money off the current 
system at the expense of the patient? PBMs, drug companies, who 
is making the money?
 Dr. Kircher. I think the answer to that question is, yes, 
all of those, at the expense of the patient. And so, I think, 
at every step in that chain that you just mentioned that there 
are inefficiencies, and likely abuse. You know, ultimately, I 
know that what I am seeing at the patient level, and at the 
physician level is where things are suffering, and that is 
where it matters the most.
 You know, people are definitely not paying me more to 
handle these prior authorizations. And answer the phone call 
from the patient, and the numerous messages in the portal I 
receive of when is my authorization going to go through, and me 
not having an answer for them.
 Mr. Grothman. Okay. Now, there are obviously a lot of costs 
that goes into the current system, so common sense would say 
that overall, if this bill passes, it will be cheaper overall, 
right, if you could immediately go to the oral drug right off 
the bat.
 Dr. Kircher. I would not assume that necessarily oral drugs 
are cheaper or less cheap than IV drugs. Sometimes IV drugs are 
more expensive. It just puts them on--this legislation is 
excellent because it puts them on par with each other, so at 
least there is some transparency in how we are covered.
 Mr. Grothman. I guess what I am trying to get to, this 
legislation is not a law today. And it is not law, somebody 
would have introduced something in past sessions, except for 
somebody is making money. So, the question for you really is, 
who is making the money? You can say. Who is making money on 
the current system that would stand in the way of this bill 
becoming a law.
 Dr. Kircher. I think PBMs. Yes. And all the middlemen in 
between.
 Mr. Grothman. Okay. Dr. Okon, I can see you wanting to say 
something.
 Mr. Okon. Excuse me, but when my wife listens to this and 
she hears you call me doctor, and she is the nurse, she will 
say there is only one medical professional in the Okon family 
and it is not him, as much as he thinks he knows about 
oncology. So, I appreciate your reference to the doctor.
 But let me say that who is making the money are the 
insurers and the PBMs in this. I mean, I am not going to deny 
that basically launch prices are too high on the pharmaceutical 
company side, but you have to understand that they have an 
ordinate control. The top insurers are the top PBMs, so they 
have total control of the marketplace.
 Mr. Grothman. So, vertical integration is part of the 
problem, too.
 Mr. Okon. Absolutely. And if I can say, consolidation--if 
you asked me one word to tell you what is wrong with our 
healthcare system, it is consolidation. And if you go online 
and you look at the color prescription for healthcare reform 
2.0, you will see it is consolidation is our problem.
 Mr. Grothman. I do not want to wander here, but the general 
perception that I know people around here, is the current 
system, which was changed so much under President Obama, was 
largely written to benefit the insurance companies. And we have 
received private briefings on not only that, but the huge cost 
of fraud under the current system that is just through the 
roof. But in any event, we will go to Ms. Randall for her 
second round.
 Ms. Randall. Thank you, Mr. Chair. I want to second the 
challenges of vertical integration and consolidation in the 
healthcare system. It is an issue that I worked a lot on in the 
Washington State legislature when I was there.
 But Dr. Kircher, you were talking about your patients, you 
know, you see them on their hardest days having to make really 
tough choices about what they can afford, what kind of 
treatment they can afford to access. And I could not help but 
think, I had a friend who was diagnosed with a very serious and 
aggressive GI cancer before her 30th birthday and, you know, 
best way to get through it was to think about money as like 
monopoly money. She is like, well, either I am going to survive 
and I will figure it out, or I will not and what does my credit 
card bill mean to anyone, which is a really challenging place 
to be for someone fighting for their life.
 As your patients are making these decisions about what they 
can afford, what other considerations, you know, are they 
sharing with you? Is it taking care of their children, their 
housing? What goes into making this decision about what is 
possible for them.
 Dr. Kircher. It is really interesting, when you talk to 
patients, they oftentimes will not bring up the finances. You 
know, you are sitting in front of them telling them, you know, 
the worst news of their life, and they do not want to share 
with their doctor that they do not--that they are worried that 
they cannot afford the medications. They will put it on their 
credit card, they will sell the house, they will do whatever 
they can for that glimmer of hope, and they do not want me to 
make decisions based on whether or not cost is an issue.
 But, you know, I oftentimes remind my patients, and have to 
remind my team and myself that these patients have lives 
outside of these four walls. Work did not stop, although they 
may not be able to go to it, their children still--you know, 
anyone who has a five-year-old knows that, I do not know if 
they care if mom does not feel well. Mom has got to do what she 
has got to do. And so, childcare continues, work continues, and 
the bills just keep piling up.
 So, when we talk about even a total, you know, an out-of-
pocket cost of $50, $100, it is not the $50, it is not the 
$100, it is that amount of money sitting on a pile of direct 
and indirect costs. And, you know, I wish that credit card bill 
would just go away, but really what it is doing is leaving a 
financial legacy to their kids and their spouse and their loved 
ones on top of them potentially passing from their cancer.
 Ms. Randall. Thank you so much. You know, Mr. Wright, you 
earlier enumerated a number of things that Congress could be 
doing to address some of the problems with rising healthcare 
costs. Can you share, again, some of your best recommendations 
so that we can ensure rising drug prices do not translate into 
patients delaying, abandoning, or going without treatment?
 Mr. Wright. Thank you, Congresswoman. I first start with 
coverage. None of this conversation means anything to people 
who are uninsured or underinsured. People who are uninsured 
live sicker, die younger, or are one emergency away from 
financial ruin. Reversing the cuts that have been made, and 
trying to further expand coverage is a direction we need to go 
to properly honor cancer patients and make sure that they are 
covered.
 Second, once they are in coverage, that coverage needs to 
be comprehensive. And that means not have untold cost-sharing 
barriers, whether it is because if it is oral or IV, or just 
because it is a cancer treatment and it is thousands of 
dollars. And so having some review and oversight over benefit 
design, whether it is standardized plans, whether it is co-pay 
caps, or other things.
 But then, basically that is basically just a cost shift 
within the insurer to then shift onto other types of cost 
sharing, or to premiums if you do not deal with the base cost 
of why the drugs are so darn expensive to begin with. And that 
means dealing with the issues of why drugs are so expensive, 
whether it is with regard to patent abuse, whether it is with 
regard to other issues of problematic practices, or just even 
just having the government negotiate for the best possible 
deal, like both President Biden and Trump did under the 
Inflation Reduction Act. That would be an appropriate way to 
expand that Medicaid negotiating power to more drugs, to more 
people across the board.
 Ms. Randall. Thank you. I hope some of those 
recommendations are things we can work on bipartisanly. I just 
have one more UC request for you, I ask unanimous consent to 
enter into the record an article from Families USA highlighting 
how the Trump Administration is prioritizing insurance 
companies over American families.
 Mr. Grothman. Without objection. Okay. We will call on 
Congressman Gosar one more time.
 Mr. Gosar. Sounds good. Mr. Wright, would you agree with 
the statement I am going to make here, ``good process builds 
good policy builds good politics''?
 Mr. Wright. Generally, yes.
 Mr. Gosar. So, we are talking about process. Now, I guess 
what we looked at, we have seen Republicans try to do this 
comprehensive healthcare, we have seen Democrats try to do it, 
and it is a failure all the time because I think we lack the 
aspect of working with our Federal system, the incubators 
called states. I think we really need to do this to find out 
how it works, how it is working for them.
 And what one may work in Arizona, does not work in 
Washington State. May work in California, but it does not work 
in New York. We have got to tailor it to that measure, and we 
do not know those answers until we do that. Would you agree?
 Mr. Wright. I have been a state advocate for 30 years 
before taking this job, I absolutely agree.
 Mr. Gosar. Mr. Okon, do you agree with that?
 Mr. Okon. Yes.
 Mr. Gosar. How about you, Doc?
 Dr. Kircher. Generally, yes.
 Mr. Gosar. Well, so I am looking at this, and I empathize 
with you so badly, because you are forced subconsciously, 
especially when you belong to a network, you are subconsciously 
geared toward that, what you know is being paid for and not 
being paid for, right? Does that make sense to you? So, you get 
this vertical integration.
 Dr. Kircher. Yes.
 Mr. Gosar. They own the docs, they own the pharmacies, they 
own the hospitals, and you are forced to do that. So, it 
subconsciously puts you in a predicament, well, I know what 
they are going to be paid for so that I can get this 
compensated, but it may not be the treatment of choice.
 Dr. Kircher. Correct. Yes. You know, we are oftentimes 
playing that calculus in our head as far as I need treatment 
fast, and what am I going to be able to get authorized quickly. 
Oftentimes, we do not have that luxury of options, but yes.
 Mr. Gosar. Boy, we are in a real mess here because this is 
just a sticky wicket because if you look everywhere, it is a 
problem. When you look at the states as a Federalist, Mr. 
Wright, how would you go about doing that? Teach us something 
we may not know.
 Mr. Wright. I mean, I think I would look at states and what 
they are doing. Again, I mentioned my past experience as an 
advocate, a consumer and patient advocate in California where 
in Covered California, they actually have a public process 
where it is not--the insurance benefit design is not done in a 
corporate boardroom, it is done in a public process that 
includes providers, that includes patient advocates, includes 
the plans themselves, and they have a little bit of a 
straightjacket of trying to hit benefit designs that hit 70, 
80, 90 percent of actuarial value. And so, there are real 
tradeoffs.
 But then they can decide, hey, in order to have the most 
valuable benefit for folks, let us actually put primary and 
preventative care in a tier that has the least cost sharing 
possible, if no cost sharing at all, even if that means a 
slightly higher hospital benefit, it means dealing with some of 
the inequities between IV versus oral treatments so there is 
not this weird dislocation where the doctor is trying to not 
just give the best clinical advice, but also trying to help the 
patient with the financial advice, which is not the forte of a 
doctor. And I think that kind of public process is actually 
really important when setting standardized plans.
 That is something--so, I do believe in the Federal system 
when, let states experiment, but when you have an idea that is 
working, then take it Federal across the land. And I think we 
are trying to do that with the oral--with the Cancer Parity 
law, which is done in 43 states, but we need to fill the gap 
for the Federal plans, and other things like that.
 Mr. Gosar. Well, see, I get to this point where, you know, 
the Federal Government does not know all. And I think we put 
artificial restraints in when we do not think we are doing it 
at all. And so, I like the marketplace, but I want the 
compassionate aspect. So, I do not know if I--I do not know how 
to get that. Do you understand where I am coming from? You 
know, I want the system to work, but I want the patient to be 
the center focus. Because she is put in a quandary as a doctor, 
she is put in a quandary, I want her to be able to say, listen, 
this is the best mechanism, the best drug for you, here is how 
to get it.
 Mr. Wright. I actually, again, agree with you on one point, 
which is I do actually think some of these kinds of public 
things will actually allow the marketplace to work better. If 
you actually have clear standardized plans, consumers can 
actually then make apples-to-apples comparison, rather than be 
confused by different plans.
 A person who is buying a coverage today has no idea if they 
are going to get--what kind of cancer they are going to get, or 
whether they should check to see if this plan does better with 
covering oral versus IV. That is not something that should be 
in somebody's mind when they are doing comparison.
 Mr. Gosar. So, first step for you would be parity with 
ERISA, right?
 Mr. Wright. I think you either do the good things at the 
Federal level, or you allow states to lift the floor.
 Mr. Gosar. Well, doesn't challenging ERISA allow you to go 
to the states more often?
 Mr. Wright. What?
 Mr. Gosar. Doesn't breaking down ERISA actually allow you 
to work with states more broadly?
 Mr. Wright. I think you can go in another direction. You 
can either allow states to do more putting the floor in place, 
or pass the rights and consumer protections at the Federal 
level.
 Mr. Gosar. Okay. Well, I thank you very much. I appreciate 
it.
 Mr. Grothman. Thank you very much. In closing, I want to 
thank our witnesses, again, for your testimony. Now we are 
going to go to closing remarks. Ms. Randall.
 Ms. Randall. I just want to thank you all for bringing your 
best ideas today to this discussion. You know, healthcare is 
such a vital issue for all Americans across the country, folks 
in red states, and blue states, in rural communities, and urban 
communities, providers who are trying to keep their doors open 
and help their patients access the care that they so need, and 
families who are making tough decisions about what they can 
afford. And I think it is definitely our responsibility to 
ensure that everyone has all the tools that they need to not 
just survive, but thrive, and that means ensuring that 
healthcare is not a direct ticket to bankruptcy for families 
who are dealing with really severe challenges. Thank you so 
much. I yield back.
 Mr. Grothman. We have had several committee hearings 
dealing with healthcare on this Subcommittee, and on the 
Committee as a whole, and it is always very depressing to hear 
the degree to which greed drives our healthcare system, and 
this is one of the most extreme examples of that.
 So, I am glad we had this hearing today. I hope the people 
who have been up here remember what they hear in this hearing. 
I will never forget it. And because it is the last hearing 
prior to the election, I do not think my bill will pass this 
session, but hopefully the people up here can--well, I think 
all of you view it favorably, we will see what we can do to 
make sure it passes last time.
 I heard similar testimony to this 14 years ago when I was 
in the Wisconsin legislature, and Wisconsin is one of the 
whatever, 42 states, or however many states have tried to do 
this, and like I said, you know, you hear about all these 
doctors and whatnot, and big insurance executives, and when you 
are sitting there as a patient, and you--if somebody is at home 
watching this hearing, it is depressing to hear how much--which 
one will make us more money drives the system, and sometimes in 
advertently. I would like to actually talk to Dr. Kircher later 
about something or other along these lines.
 In any event, I want to thank our witnesses for their 
testimony today. I now yield--we have taken care of that. With 
[sic] and without objection, all Members have five legislative 
days within which to submit materials and additional written 
questions for the witnesses. If there is no further business, 
without objection, the Subcommittee stands adjourned.

 [all]